Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- SPORVIGILANCE Targets Safer Medicines and Billion-Euro Savings for Global Pharma Facing EU IDMP FinesLONDON, September 28, 2026--British regulatory technology company SPORVIGILANCE is targeting one of global pharma’s major compliance challenges with a platform offering a faster route to IDMP and SPOR readiness, compliance and governance.
- Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate UpdateDaix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today reported its financial information for the first half of 2026, ended June 30, 2026, including its cash position, cash flows and revenues, and provided a corporate update.
- QIAGEN N.V.QIAGEN Completes U.S. QIAstat-Dx Bloodstream Infection Portfolio With FDA Clearance of New Bacteria Detection PanelGERMANTOWN, Md. & VENLO, Netherlands, September 28, 2026--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that U.S.
- National Women’s Health and Fitness Day 2026: Nadula Encourages Women to Move Freely With Comfortable, Secure Hair SolutionsNadula encourages women to challenge that misconception. You can absolutely wear a wig while working out and remain both beautiful and comfortable.
- Yili GroupYili Shares China's Whole-Value-Chain Dairy Symbiosis Model at FAO Global ConferenceYili Group presented a China-based model for whole-value-chain symbiosis at the Food and Agriculture Organization of the United Nations' (FAO) inaugural Global Conference for Actions on One Health in Agrifood Systems. One Health seeks to sustainably...
- Akeso, Inc.Akeso Announces First Patient Enrolled in Global Phase III Trial of Cadonilimab Versus Nivolumab in First-Line Gastric CancerAkeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicenter Phase III head-to-head trial evaluating cadonilimab, Akeso's first-in-class PD-1/CTLA-4...
- Cuvo HealthCuvo Health Publishes 2026 State-by-State Virtual Clinic Compliance Report: 33 of 51 Jurisdictions Restrict the Corporate Practice of MedicineFree 51-jurisdiction dataset maps compact licensing, telehealth registration, nurse practitioner authority and MSO rules for white-label virtual clinics and digital health startups. Only 14 states offer out-of-state physicians a telehealth registration or telemedicine license. WILMINGTON,...
- ITM and Lumara Bio Announce Real-World Re-treatment Data and Dosimetry Results from COMPETE for ¹⁷⁷Luedotreotide (ITM-11) in GEP-NETs at ASTRO 2026ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Lumara Bio, a dedicated oncology therapeutics division of ITM, today announced encouraging new data of non-carrier-added (n.c.a.) 177Lu-edotreotide in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The findings were presented in two posters at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting, held from September 26 – 30, 2026 in Boston, Massachusetts.
- THE ROSEN LAW FIRM, P. A.HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud LawsuitRosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026 lead...
- Hagens Berman Sobol Shapiro LLPCAPR INVESTOR DEADLINE: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 DeadlineHagens Berman Sobol Shapiro LLP-a national plaintiffs' rights law firm with a premier securities practice group-notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the upcoming September 28, 2026 lead plaintiff deadline in the ongoing securities class action. This alert follows the U.S. Food and Drug Administration's (FDA) recent decision to extend the review period for Capricor's Biologics License Application...
- Leo Cancer CareLeo Cancer Care Brings Into Clinical Use an Upright Radiotherapy Platform Cleared for Use With Any Radiation BeamUpright. From Concept to Clinical Reality — Leo Cancer Care is marking a defining moment for radiation oncology as upright radiotherapy moves from concept to clinical reality. The Upright Platform is designed to be beam-agnostic and cleared for...
- Fuse Oncology, Inc.Fuse Oncology to Showcase S!GNAL Workflow Experience at ASTRO 2026Potential workflow illustrates how patient workflow coordination in GE HealthCare's Intelligent Radiation Therapy™ (iRT) software solution could connect to targeted charge review in S!GNAL — Fuse Oncology today announced plans to showcase a...